These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 18923648)

  • 1. Anti-HIV-1 response elicited in rabbits by anti-idiotype monoclonal antibodies mimicking the CD4-binding site.
    Burioni R; Mancini N; De Marco D; Clementi N; Perotti M; Nitti G; Sassi M; Canducci F; Shvela K; Bagnarelli P; Mascola JR; Clementi M
    PLoS One; 2008; 3(10):e3423. PubMed ID: 18923648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyperglycosylated stable core immunogens designed to present the CD4 binding site are preferentially recognized by broadly neutralizing antibodies.
    Ingale J; Tran K; Kong L; Dey B; McKee K; Schief W; Kwong PD; Mascola JR; Wyatt RT
    J Virol; 2014 Dec; 88(24):14002-16. PubMed ID: 25253346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutralizing recombinant human antibodies to a conformational V2- and CD4-binding site-sensitive epitope of HIV-1 gp120 isolated by using an epitope-masking procedure.
    Ditzel HJ; Binley JM; Moore JP; Sodroski J; Sullivan N; Sawyer LS; Hendry RM; Yang WP; Barbas CF; Burton DR
    J Immunol; 1995 Jan; 154(2):893-906. PubMed ID: 7529290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutralization of HIV-1 by anti-idiotypes to monoclonal anti-CD4. Potential for idiotype immunization against HIV.
    Sutor GC; Dreikhausen U; Vähning U; Jurkiewicz E; Hunsmann G; Lundin K; Schedel I
    J Immunol; 1992 Aug; 149(4):1452-61. PubMed ID: 1500724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An HIV-1 Env-Antibody Complex Focuses Antibody Responses to Conserved Neutralizing Epitopes.
    Chen Y; Wilson R; O'Dell S; Guenaga J; Feng Y; Tran K; Chiang CI; Arendt HE; DeStefano J; Mascola JR; Wyatt RT; Li Y
    J Immunol; 2016 Nov; 197(10):3982-3998. PubMed ID: 27815444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural mimicry of CD4 by a cross-reactive HIV-1 neutralizing antibody with CDR-H2 and H3 containing unique motifs.
    Prabakaran P; Gan J; Wu YQ; Zhang MY; Dimitrov DS; Ji X
    J Mol Biol; 2006 Mar; 357(1):82-99. PubMed ID: 16426633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD4-imitating human antibodies in HIV infection and anti-idiotypic vaccination.
    Deckert PM; Ballmaier M; Lang S; Deicher H; Schedel I
    J Immunol; 1996 Jan; 156(2):826-33. PubMed ID: 8543839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-idiotype monoclonal antibody elicits broadly neutralizing anti-gp120 antibodies in monkeys.
    Kang CY; Nara P; Chamat S; Caralli V; Chen A; Nguyen ML; Yoshiyama H; Morrow WJ; Ho DD; Köhler H
    Proc Natl Acad Sci U S A; 1992 Apr; 89(7):2546-50. PubMed ID: 1557358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monoclonal anti-idiotypic antibody mimicking the principal neutralization site in HIV-1 GP120 induces HIV-1 neutralizing antibodies in rabbits.
    Fung MS; Sun CR; Liou RS; Gordon W; Chang NT; Chang TW; Sun NC
    J Immunol; 1990 Oct; 145(7):2199-206. PubMed ID: 2398276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation and Characterization of a Bivalent HIV-1 Subtype C gp120 Protein Boost for Proof-of-Concept HIV Vaccine Efficacy Trials in Southern Africa.
    Zambonelli C; Dey AK; Hilt S; Stephenson S; Go EP; Clark DF; Wininger M; Labranche C; Montefiori D; Liao HX; Swanstrom RI; Desaire H; Haynes BF; Carfi A; Barnett SW
    PLoS One; 2016; 11(7):e0157391. PubMed ID: 27442017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A broad range of mutations in HIV-1 neutralizing human monoclonal antibodies specific for V2, V3, and the CD4 binding site.
    Li L; Wang XH; Williams C; Volsky B; Steczko O; Seaman MS; Luthra K; Nyambi P; Nadas A; Giudicelli V; Lefranc MP; Zolla-Pazner S; Gorny MK
    Mol Immunol; 2015 Aug; 66(2):364-74. PubMed ID: 25965315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-Leu3a induces combining site-related anti-idiotypic antibody without inducing anti-HIV activity.
    Reeves JP; Buck D; Berkower I; Murphy D; Epstein SL
    AIDS Res Hum Retroviruses; 1991 Jan; 7(1):55-63. PubMed ID: 2015115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-idiotypic antibodies to the third variable domain of gp120 induce an anti-HIV-1 antibody response in mice.
    Boudet F; Theze J; Zouali M
    Virology; 1994 Apr; 200(1):176-88. PubMed ID: 7510435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Temporal development and prognostic value of antibody response to the major neutralizing epitopes of gp120 during HIV-1 infection.
    Turbica I; Simon F; Besnier JM; LeJeune B; Choutet P; Goudeau A; Barin F
    J Med Virol; 1997 Jul; 52(3):309-15. PubMed ID: 9210041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA vaccine molecular adjuvants SP-D-BAFF and SP-D-APRIL enhance anti-gp120 immune response and increase HIV-1 neutralizing antibody titers.
    Gupta S; Clark ES; Termini JM; Boucher J; Kanagavelu S; LeBranche CC; Abraham S; Montefiori DC; Khan WN; Stone GW
    J Virol; 2015 Apr; 89(8):4158-69. PubMed ID: 25631080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An engineered mutant of HIV-1 gp120 formulated with adjuvant Quil A promotes elicitation of antibody responses overlapping the CD4-binding site.
    Ahmed FK; Clark BE; Burton DR; Pantophlet R
    Vaccine; 2012 Jan; 30(5):922-30. PubMed ID: 22142583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PGV04, an HIV-1 gp120 CD4 binding site antibody, is broad and potent in neutralization but does not induce conformational changes characteristic of CD4.
    Falkowska E; Ramos A; Feng Y; Zhou T; Moquin S; Walker LM; Wu X; Seaman MS; Wrin T; Kwong PD; Wyatt RT; Mascola JR; Poignard P; Burton DR
    J Virol; 2012 Apr; 86(8):4394-403. PubMed ID: 22345481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A potent, neutralizing human monoclonal antibody against a unique epitope overlapping the CD4-binding site of HIV-1 gp120 that is broadly conserved across North American and African virus isolates.
    Pinter A; Honnen WJ; Racho ME; Tilley SA
    AIDS Res Hum Retroviruses; 1993 Oct; 9(10):985-96. PubMed ID: 7506556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design of an Escherichia coli expressed HIV-1 gp120 fragment immunogen that binds to b12 and induces broad and potent neutralizing antibodies.
    Bhattacharyya S; Singh P; Rathore U; Purwar M; Wagner D; Arendt H; DeStefano J; LaBranche CC; Montefiori DC; Phogat S; Varadarajan R
    J Biol Chem; 2013 Apr; 288(14):9815-9825. PubMed ID: 23430741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complementary and synergistic activities of anti-V3, CD4bs and CD4i antibodies derived from a single individual can cover a wide range of HIV-1 strains.
    Ramirez Valdez KP; Kuwata T; Maruta Y; Tanaka K; Alam M; Yoshimura K; Matsushita S
    Virology; 2015 Jan; 475():187-203. PubMed ID: 25486586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.